1140PDPhase I study of KN035, a novel fusion Anti-PD-L1 antibody administered subcutaneously in patients with advanced solid tumors in the USA. (23rd October 2018) - Papadopoulos, K P; Harb, W; Lu, N; Ma, X; He, Y; Yuan, L; Fu, M; Lin, Y; Xu, W; Wang, X; Wang, P; Xu, T; et al.